World Hepatitis day July 28th, 2024. It's time for action.
This Article supports SDG 3 by assessing the effectiveness of a hepatitis B model of care in Australia, suggesting that the model, involving primary health care, could be rolled out nationally or internationally. The authors suggest that the model could have positive implications particularly for low-income and middle-income countries.
This Article supports SDG 3 by evaluating a hepatitis B screening programme in which members of the West African community in the Bronx were offered hepatitis B testing when they attended a blood pressure clinic visit following an educational intervention about hypertension. Almost all participants accepted to have hepatitis B screening, showing the effectiveness of its being linked to blood pressure testing.
This Article supports SDG3 by evaluating sex and gender disparities in terms of risk factors, treatment uptake/completion, and virological outcomes for hepatitis C, finding differences between men and women in, for example, exposure to different risk factors and likelihood of commencing treatment. More attention is needed in research to these disparities and how they could be addressed
This Article supports SDG3 by investigating the barriers to receiving childhood hepatitis B vaccines in Laos. The findings suggest that socioeconomic factors play a substantial role in the variation in vaccine coverage, particularly household income and education.
This Article supports SDG 3 by demonstrating the effectiveness of assisted partner services in Kenya to test the partners of people who inject drugs for HIV and hepatitis C, and support linkage to and engagement in care among those who are positive for either infection.
Nearly 2.4% of global deaths in 2019 were attributed to cirrhosis, which has increased since 2017. Liver transplantation (LT) is accepted as a lifesaving therapy for patients with complications of cirrhosis or hepatocellular cancer, but there are several barriers toward equitable access. This article outlines ways to reduce the disparities
This Article supports SDG 3 by arguing that people under community correction supervision (probation or parole) are a large population of individuals at risk of viral hepatitis, to whom little attention has thus far been paid. Targeting hepatitis testing and treatment services at this population would be feasible and effective in reducing hepatitis incidence.
This Article supports SDG 3 by assessing the prevalence of hepatitis B, C, and delta virus in French Polynesia. The findings suggest that the HBV vaccination policy is effective and that HCV and HDV have very low levels of transmission, although some areas did have higher HBV prevalence, warrenting improved vaccine coverage and awareness.
This Article supports SDG 3 by showing that providing hepatitis C testing services in pharmacies would be beneficial in increasing case detection, in keeping with growing evidence showing the benefits of providing hepatitis services in community settings. Further research is needed to evaluate the provision of hepatitis C treatment, and hepatitis B testing and treatment, in pharmacies
This Review supports SDG 3 by describing the national response to hepatitis B and C virus in Viet Nam and the Philippines, finding that although both countries have robust policies, there are differences between them in political commitment, funding, and engagement
Drug-induced liver injury (DILI) is responsible for 10% of cases of hepatitis in adults, and 13–17% of cases of fulminant hepatitis. The article proposes a way forward and roadmap to prioritize DILI research and clinical science.
This Article supports SDG 3 by estimating the prevalence of chronic hepatitis C virus infection in Europe and suggesting that EU countries need to scale up testing and treatment linkage, as well as review overall strategies for hepatitis prevention.
This Article supports SDG 3 by showing that mobile health clinics can be a feasible and effective way of providing hepatitis C services to underserved, at-risk populations who face barriers to care. Policymakers should consider implementing such programmes in order to increase diagnosis and treatment rates and improve outcomes among these populations.
This Article supports SDG 3 by showing that there is a high global seroprevalence of HCV infection among pregnant women (estimated at 2.2–5.3 million cases worldwide), and particularly in lower-income settings. The authors suggest policy implications, such as expanding screening programmes for pregnant women and women of childbearing age, particularly in lower-income settings.
This Article supports SDG 3 by providing estimates of HIV and hepatitis C testing and treatment uptake among people who inject drugs. Data availability was variable, and where data were available, uptake was generally suboptimal, indicating a need for countries to implement targeted interventions to improved testing, linkage to care, and treatment among people who inject drugs
This Series paper supports SDG 3 by evaluating existing and emerging vaccines and vaccination campaigns against hepatitis B virus and other sexually transmitted infections, as well as other interventions such as PrEP for HIV
This Article supports SDG 3 by showing that there is a high burden of hepatitis B and C infection and related liver diseases in Europe, suggesting the need for increased investment in prevention, detection, and treatment strategies is needed to bring Europe closer to the goal of elimination by 2030.
This Article supports SDG 3 by showing that international transmission of hepatitis C virus has occurred in recent years among men who have sex with men. This suggests that international coordination will be needed for microelimination in this population.
This Review supports SDG 3 by assessing the availablility of data for reporting elimination targets of mother-to-child transmission of HIV, hepatitis B, and syphilis, and reports on progress towards these targets in Pacific Island countries and territories.
This review supports SDG 3 as despite available antiviral therapy, hepatitis C virus (HCV) remains a global health burden and a prophylactic vaccine would help to eliminate the risk to develop chronic liver diseases. This paper uses data to draw a simplified model of virus entry, which highlights gaps in our current knowledge that warrant further research to fully understand this process at the atomic level.
This Article supports SDG 3 by evaluating alanine transaminase antiviral treatments for hepatitis B virus infection in China. The authors suggest the optimal treatment coverage for both cost-effectiveness and mortality reduction based on their findings
This Article supports SDG 3 as the results show that two doses of the HEV 239 vaccine produces broad and likely functional immune responses against HEV that remain for at least two years. The safety profile was acceptable and a phase four study of HEV 239 in rural Bangladesh is feasible.
This article supports SDG 3 as chronic hepatitis B (HBV) and C virus (HCV) infections represent significant public health issues internationally. This paper aims to evaluate the efficacy of hepatitis B vaccination in HCV-related chronic liver disease and identify possible factors that may contribute to hypo-responsiveness in those patients.
This review supports SDG3 by detailing the current fundamental knowledge of HDV lifecycle and review antiviral treatments under development against this virus, outlining their respective mechanisms-of-action. Finally, it describes the antiviral effect these compounds are showing in ongoing clinical trials, discussing their promise and potential pitfalls for managing HDV infected patients.
This article supports SDG 3 by providing accurate folds of Hepatitis E Virus' five domains. The work highlights that there is no canonical protease encoded in pORF1 and that flexibility in several functionally important regions rather than proteolytic processing may serve to regulate HEV RNA synthesis
Introduction and Objectives: We initiated this multicenter study to integrate important risk factors to create a nomogram for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) for clinician decision-making. Patients and Methods: Between April 2011 and March 2022, 2281 HCC patients with an HBV-related diagnosis were included. All patients were randomly divided into two groups in a ratio of 7:3 (training cohort, n = 1597; validation cohort, n = 684). The nomogram was built in the training cohort via Cox regression model and validated in the validation cohort.
This article supports SDG 3 as understanding the role of HCV core proteins in viral diseases is crucial to elucidating disease mechanisms and identifying potential drug targets. However, purification challenges may hinder the comprehensive elucidation of the structure and biochemical properties of HCV core proteins.
This content aligns with Goal 3: Good Health by providing a better understanding of the fundamental biology of the hepatitis viruses and their pathogenesis that may provide new clues to improve the prevention and treatments for these human pathogens.
This content aligns with Goal 3: Good Health by summarizing the current molecular methods of detection and quantification of hepatitis virus genomes, with special emphasis on the assays commercially available and applicable for clinical use.
This content aligns with Goal 3: Good Health. Infectious hepatitis during childhood is classified both for clinical and academic purposes as acute or chronic, the latter carrying the highest burden of morbidity and mortality.
This content aligns with Goal 3: Good Health. Hepatitis B remains a worrying health problem for several countries. Although vaccination has clearly been shown to be very effective in the prevention and control of the disease globally, the emergence of mutant resistant liver infections is of concern. Thus the development of new common vaccines for the prevention of all types of hepatitis is warranted.
This content aligns with Goal 3: Good Health, this chapter aims at elucidating the main characteristics of AIH, PBC, and PSC, with particular interest for the clinical manifestations, pathogenesis, autoantibodies, and therapeutic options.
This content aligns with Goal 3: Good Health. Presents the successful influenza vaccines (using hemagglutinin and neuraminidase proteins), hepatitis B surface antigen vaccine, and the human papillomavirus vaccines targeting viral capsid proteins.
This content aligns with Goal 3: Good Health. As per World Health Organization (WHO) recommendations, it is required to implement the evaluation studies of ethnomedicines for HIV/AIDS, malaria, tuberculosis, and other infectious treatments, to find effective and economical therapeutic agents.
This content aligns with Goal 3: Good Health. Provides a firm understanding of the undulating interplay between liver graft function and a patient’s risk for infection.